[Form 4] Manhattan Associates Inc Insider Trading Activity

Q: How did PRDO's revenue perform in Q2 2025?

Revenue rose 25.7 % year-over-year to $209.6 million , aided by the USAHS acquisition.

Q: What was Perdoceo's diluted EPS for the quarter?

Diluted EPS increased to $0.62 , up from $0.57 in Q2 2024.

Q: How much cash and short-term investments does PRDO have?

As of June 30 2025 the company held $659.6 million in cash, equivalents and short-term investments.

Q: What is the status of share repurchases?

PRDO bought back 1.6 million shares for $46.1 m YTD; a new $75 m authorization begins 7/31/25.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Q2 2025 snapshot (Perdoceo Education – PRDO):

Revenue surged 25.7 % YoY to $209.6 m, aided by the Dec-24 USAHS acquisition (18 % of quarterly sales) and continued growth at legacy units.
Operating income climbed 11.7 % to $51.4 m; net income up 6.8 % to $41.0 m, delivering diluted EPS of $0.62 versus $0.57.
YTD revenue $422.6 m (+26 %), net income $84.7 m (+8.8 %). Operating cash flow strengthened to $143.9 m (+55 %).
Cash, equivalents & short-term investments reached $659.6 m after $46.1 m of buybacks (1.6 m shares) and $17.7 m in dividends; only $1 m remained under the prior $50 m authorization, but a new $75 m program was approved 7/31/25.
Segment mix: CTU 56 % of revenue, AIUS 26 %, USAHS 18 % (-$2.0 m YTD operating loss during integration).
Gross deferred revenue rose to $113.6 m, reflecting higher billing and enrollment; allowance for credit losses stable at $42.3 m.
Balance sheet still debt-light; a $56.8 m failed sale-leaseback created a financing liability. Total cash plus investments exceed all liabilities by ~$675 m.
Effective tax rate eased to 27.0 % (benefit from stock-comp and reserve releases).
Regulatory/legal: DOJ False Claims Act suit and new CID remain unresolved; litigation reserve $1.5 m.

Takeaway: Solid top-line growth and cash generation offset margin dilution from USAHS and higher depreciation. Ample liquidity supports continued buybacks and dividends, while integration execution and regulatory outcomes are key watch items.

Riepilogo Q2 2025 (Perdoceo Education – PRDO):

I ricavi sono aumentati del 25,7% su base annua, raggiungendo 209,6 milioni di dollari, grazie all'acquisizione di USAHS a dicembre 2024 (che rappresenta il 18% delle vendite trimestrali) e alla crescita continua delle unità storiche.
L'utile operativo è cresciuto dell'11,7%, arrivando a 51,4 milioni di dollari; l'utile netto è salito del 6,8% a 41,0 milioni di dollari, con un utile per azione diluito di 0,62 dollari rispetto a 0,57 dollari.
I ricavi da inizio anno ammontano a 422,6 milioni di dollari (+26%), con un utile netto di 84,7 milioni (+8,8%). Il flusso di cassa operativo si è rafforzato a 143,9 milioni di dollari (+55%).
La liquidità, equivalenti e investimenti a breve termine hanno raggiunto 659,6 milioni di dollari dopo riacquisti per 46,1 milioni di dollari (1,6 milioni di azioni) e dividendi per 17,7 milioni; è rimasto solo 1 milione sotto la precedente autorizzazione di 50 milioni, ma è stato approvato un nuovo programma da 75 milioni il 31/07/25.
Composizione per segmento: CTU 56% dei ricavi, AIUS 26%, USAHS 18% (con una perdita operativa di 2,0 milioni da inizio anno durante l'integrazione).
I ricavi differiti lordi sono saliti a 113,6 milioni, riflettendo un aumento di fatturazione e iscrizioni; l'accantonamento per perdite su crediti è stabile a 42,3 milioni.
Lo stato patrimoniale rimane con basso indebitamento; una vendita-leaseback fallita da 56,8 milioni ha generato una passività finanziaria. La liquidità totale più investimenti supera tutte le passività di circa 675 milioni.
L'aliquota fiscale effettiva è scesa al 27,0% (benefici da compensi azionari e rilascio di riserve).
Regolamentazione/legale: la causa DOJ per False Claims Act e il nuovo CID sono ancora irrisolti; la riserva per contenziosi è di 1,5 milioni.

Conclusione: Una solida crescita dei ricavi e la generazione di cassa compensano la diluizione dei margini dovuta a USAHS e all’aumento degli ammortamenti. Un’ampia liquidità supporta ulteriori riacquisti e dividendi, mentre l’esecuzione dell’integrazione e gli esiti regolamentari restano elementi chiave da monitorare.

Resumen Q2 2025 (Perdoceo Education – PRDO):

Los ingresos aumentaron un 25,7% interanual hasta 209,6 millones de dólares, impulsados por la adquisición de USAHS en diciembre de 2024 (18% de las ventas trimestrales) y el crecimiento continuo de las unidades históricas.
El ingreso operativo creció un 11,7% hasta 51,4 millones; el ingreso neto subió un 6,8% a 41,0 millones, con una utilidad diluida por acción de 0,62 frente a 0,57.
Los ingresos acumulados en el año alcanzaron 422,6 millones (+26%), con un ingreso neto de 84,7 millones (+8,8%). El flujo de caja operativo se fortaleció a 143,9 millones (+55%).
El efectivo, equivalentes e inversiones a corto plazo llegaron a 659,6 millones tras recompras por 46,1 millones (1,6 millones de acciones) y dividendos por 17,7 millones; solo quedaba 1 millón bajo la autorización previa de 50 millones, pero se aprobó un nuevo programa de 75 millones el 31/07/25.
Composición por segmentos: CTU 56% de los ingresos, AIUS 26%, USAHS 18% (pérdida operativa de 2,0 millones en el año durante la integración).
Los ingresos diferidos brutos subieron a 113,6 millones, reflejando mayor facturación e inscripciones; la provisión para pérdidas crediticias se mantuvo estable en 42,3 millones.
El balance sigue con bajo nivel de deuda; una venta y arrendamiento fallida por 56,8 millones generó un pasivo financiero. El total de efectivo más inversiones supera todos los pasivos en aproximadamente 675 millones.
La tasa impositiva efectiva bajó al 27,0% (beneficio por compensación en acciones y liberación de reservas).
Regulatorio/legal: la demanda del DOJ bajo la Ley de Reclamaciones Falsas y el nuevo CID siguen sin resolverse; la reserva para litigios es de 1,5 millones.

Conclusión: Un sólido crecimiento en ingresos y generación de efectivo compensan la dilución del margen por USAHS y mayor depreciación. La amplia liquidez respalda recompras y dividendos continuos, mientras que la ejecución de la integración y los resultados regulatorios son aspectos clave a vigilar.

Résumé T2 2025 (Perdoceo Education – PRDO) :

Le chiffre d'affaires a bondi de 25,7 % en glissement annuel pour atteindre 209,6 M$, soutenu par l'acquisition de USAHS en décembre 2024 (18 % des ventes trimestrielles) et la croissance continue des unités historiques.
Le résultat opérationnel a progressé de 11,7 % à 51,4 M$ ; le résultat net a augmenté de 6,8 % à 41,0 M$, avec un BPA dilué de 0,62 $ contre 0,57 $.
Le chiffre d'affaires cumulé depuis le début de l'année s'élève à 422,6 M$ (+26 %), le résultat net à 84,7 M$ (+8,8 %). Les flux de trésorerie opérationnels se sont renforcés à 143,9 M$ (+55 %).
La trésorerie, équivalents et placements à court terme ont atteint 659,6 M$ après des rachats d'actions pour 46,1 M$ (1,6 M d'actions) et des dividendes de 17,7 M$ ; il ne restait que 1 M$ sous l'autorisation précédente de 50 M$, mais un nouveau programme de 75 M$ a été approuvé le 31/07/25.
Répartition par segment : CTU 56 % du chiffre d'affaires, AIUS 26 %, USAHS 18 % (perte opérationnelle de 2,0 M$ depuis le début de l'année pendant l'intégration).
Le chiffre d'affaires différé brut est passé à 113,6 M$, reflétant une facturation et des inscriptions accrues ; la provision pour pertes sur créances est stable à 42,3 M$.
Le bilan reste peu endetté ; une cession-bail échouée de 56,8 M$ a généré un passif financier. La trésorerie totale plus les investissements dépassent les passifs de ~675 M$.
Le taux d'imposition effectif a diminué à 27,0 % (bénéfice des compensations en actions et des reprises de provisions).
Réglementaire/juridique : la plainte du DOJ pour violation du False Claims Act et la nouvelle CID restent non résolues ; la provision pour litiges est de 1,5 M$.

Conclusion : Une solide croissance du chiffre d'affaires et une génération de trésorerie compensent la dilution des marges liée à USAHS et à l'augmentation des amortissements. Une liquidité abondante soutient les rachats d'actions et les dividendes continus, tandis que l'exécution de l'intégration et les résultats réglementaires restent des points clés à surveiller.

Q2 2025 Überblick (Perdoceo Education – PRDO):

Der Umsatz stieg im Jahresvergleich um 25,7 % auf 209,6 Mio. USD, unterstützt durch die Übernahme von USAHS im Dezember 2024 (18 % des Quartalsumsatzes) und anhaltendes Wachstum bei den Bestandsunternehmen.
Das operative Ergebnis kletterte um 11,7 % auf 51,4 Mio. USD; der Nettogewinn stieg um 6,8 % auf 41,0 Mio. USD, was ein verwässertes Ergebnis je Aktie von 0,62 USD gegenüber 0,57 USD bedeutet.
Der Umsatz seit Jahresbeginn beträgt 422,6 Mio. USD (+26 %), der Nettogewinn 84,7 Mio. USD (+8,8 %). Der operative Cashflow verbesserte sich auf 143,9 Mio. USD (+55 %).
Barmittel, Äquivalente und kurzfristige Investitionen erreichten 659,6 Mio. USD nach Aktienrückkäufen im Wert von 46,1 Mio. USD (1,6 Mio. Aktien) und Dividenden von 17,7 Mio. USD; unter der vorherigen Genehmigung von 50 Mio. USD verblieb nur noch 1 Mio., aber ein neues Programm über 75 Mio. USD wurde am 31.07.25 genehmigt.
Segmentmix: CTU 56 % des Umsatzes, AIUS 26 %, USAHS 18 % (operativer Verlust von 2,0 Mio. USD seit Jahresbeginn während der Integration).
Die Brutto-Rückstellungen für Umsatzerlöse stiegen auf 113,6 Mio. USD, was höhere Abrechnungen und Einschreibungen widerspiegelt; die Wertberichtigung für Forderungsausfälle blieb mit 42,3 Mio. USD stabil.
Die Bilanz bleibt schuldenarm; ein gescheiterter Sale-Leaseback in Höhe von 56,8 Mio. USD führte zu einer Finanzverbindlichkeit. Barmittel plus Investitionen übersteigen alle Verbindlichkeiten um ca. 675 Mio. USD.
Der effektive Steuersatz sank auf 27,0 % (Vorteil durch Aktienvergütungen und Rückstellungen).
Regulatorisch/rechtlich: DOJ-Klage nach dem False Claims Act und neue CID sind noch offen; Rückstellung für Rechtsstreitigkeiten beträgt 1,5 Mio. USD.

Fazit: Solides Umsatzwachstum und Cash-Generierung kompensieren Margenverwässerung durch USAHS und höhere Abschreibungen. Ausreichende Liquidität unterstützt weitere Aktienrückkäufe und Dividenden, während die Integration und regulatorische Ergebnisse wichtige Beobachtungspunkte bleiben.

Positive

Revenue growth 25.7 % YoY driven by both organic enrollment and USAHS acquisition.
Net income up 6.8 % and diluted EPS $0.62, marking the fifth straight quarterly EPS increase.
Operating cash flow $143.9 m exceeds net income, boosting liquidity to $659.6 m.
Board authorized new $75 m share-repurchase program after nearly exhausting prior plan.
Minimal long-term debt; cash and investments comfortably cover all liabilities.

Negative

Operating expenses up 31 % YoY, compressing operating margin from 27.6 % to 24.5 %.
USAHS posted a $2.0 m YTD operating loss, indicating integration/margin risks.
$56.8 m failed sale-leaseback liability adds fixed financing cost through 2050.
Ongoing DOJ False Claims Act litigation and new CID could lead to material penalties or Title IV restrictions.
Bad-debt expense rose to $13.0 m YTD, reflecting higher credit-loss provisioning.

Insights

TL;DR – Revenue beats and cash builds; margins tighten, but capital return intact.

Perdoceo posted double-digit revenue and EPS gains despite elevated expenses tied to the USAHS acquisition. Free cash flow conversion remains robust (OCF > net income), and $660 m of liquid assets provides exceptional balance-sheet optionality. Share count fell 1 % YTD and a fresh $75 m authorization signals confidence. Key positives include 26 % YTD revenue growth, 19.6 % net margin and minimal leverage. Offsets are higher depreciation (+230 %) and integration drag that pushed USAHS into a modest loss. Valuation catalysts rest on successful USAHS margin expansion and resolution of DOJ matters. Overall impact viewed as moderately positive for equity holders.

TL;DR – Strong finances, but legal clouds and sale-leaseback liability temper outlook.

The filing flags persistent regulatory exposure: an active False Claims Act suit and a fresh DOJ CID probing admissions pay and Fast Track credits. Historical precedents indicate settlements can reach eight-figure sums and impose operating restrictions. Litigation reserve is only $1.5 m, suggesting potential under-provisioning. The failed sale-leaseback adds $56.8 m of financing obligations plus interest, marginally increasing fixed-cost leverage. Bad-debt expense also ticked up 8 %. While liquidity is ample, unresolved probes could curtail future cash deployment and affect Title IV eligibility. I classify the disclosure as medium-risk, counter-balancing otherwise healthy fundamentals.

Riepilogo Q2 2025 (Perdoceo Education – PRDO):

I ricavi sono aumentati del 25,7% su base annua, raggiungendo 209,6 milioni di dollari, grazie all'acquisizione di USAHS a dicembre 2024 (che rappresenta il 18% delle vendite trimestrali) e alla crescita continua delle unità storiche.
L'utile operativo è cresciuto dell'11,7%, arrivando a 51,4 milioni di dollari; l'utile netto è salito del 6,8% a 41,0 milioni di dollari, con un utile per azione diluito di 0,62 dollari rispetto a 0,57 dollari.
I ricavi da inizio anno ammontano a 422,6 milioni di dollari (+26%), con un utile netto di 84,7 milioni (+8,8%). Il flusso di cassa operativo si è rafforzato a 143,9 milioni di dollari (+55%).
La liquidità, equivalenti e investimenti a breve termine hanno raggiunto 659,6 milioni di dollari dopo riacquisti per 46,1 milioni di dollari (1,6 milioni di azioni) e dividendi per 17,7 milioni; è rimasto solo 1 milione sotto la precedente autorizzazione di 50 milioni, ma è stato approvato un nuovo programma da 75 milioni il 31/07/25.
Composizione per segmento: CTU 56% dei ricavi, AIUS 26%, USAHS 18% (con una perdita operativa di 2,0 milioni da inizio anno durante l'integrazione).
I ricavi differiti lordi sono saliti a 113,6 milioni, riflettendo un aumento di fatturazione e iscrizioni; l'accantonamento per perdite su crediti è stabile a 42,3 milioni.
Lo stato patrimoniale rimane con basso indebitamento; una vendita-leaseback fallita da 56,8 milioni ha generato una passività finanziaria. La liquidità totale più investimenti supera tutte le passività di circa 675 milioni.
L'aliquota fiscale effettiva è scesa al 27,0% (benefici da compensi azionari e rilascio di riserve).
Regolamentazione/legale: la causa DOJ per False Claims Act e il nuovo CID sono ancora irrisolti; la riserva per contenziosi è di 1,5 milioni.

Resumen Q2 2025 (Perdoceo Education – PRDO):

Los ingresos aumentaron un 25,7% interanual hasta 209,6 millones de dólares, impulsados por la adquisición de USAHS en diciembre de 2024 (18% de las ventas trimestrales) y el crecimiento continuo de las unidades históricas.
El ingreso operativo creció un 11,7% hasta 51,4 millones; el ingreso neto subió un 6,8% a 41,0 millones, con una utilidad diluida por acción de 0,62 frente a 0,57.
Los ingresos acumulados en el año alcanzaron 422,6 millones (+26%), con un ingreso neto de 84,7 millones (+8,8%). El flujo de caja operativo se fortaleció a 143,9 millones (+55%).
El efectivo, equivalentes e inversiones a corto plazo llegaron a 659,6 millones tras recompras por 46,1 millones (1,6 millones de acciones) y dividendos por 17,7 millones; solo quedaba 1 millón bajo la autorización previa de 50 millones, pero se aprobó un nuevo programa de 75 millones el 31/07/25.
Composición por segmentos: CTU 56% de los ingresos, AIUS 26%, USAHS 18% (pérdida operativa de 2,0 millones en el año durante la integración).
Los ingresos diferidos brutos subieron a 113,6 millones, reflejando mayor facturación e inscripciones; la provisión para pérdidas crediticias se mantuvo estable en 42,3 millones.
El balance sigue con bajo nivel de deuda; una venta y arrendamiento fallida por 56,8 millones generó un pasivo financiero. El total de efectivo más inversiones supera todos los pasivos en aproximadamente 675 millones.
La tasa impositiva efectiva bajó al 27,0% (beneficio por compensación en acciones y liberación de reservas).
Regulatorio/legal: la demanda del DOJ bajo la Ley de Reclamaciones Falsas y el nuevo CID siguen sin resolverse; la reserva para litigios es de 1,5 millones.

Résumé T2 2025 (Perdoceo Education – PRDO) :

Le chiffre d'affaires a bondi de 25,7 % en glissement annuel pour atteindre 209,6 M$, soutenu par l'acquisition de USAHS en décembre 2024 (18 % des ventes trimestrielles) et la croissance continue des unités historiques.
Le résultat opérationnel a progressé de 11,7 % à 51,4 M$ ; le résultat net a augmenté de 6,8 % à 41,0 M$, avec un BPA dilué de 0,62 $ contre 0,57 $.
Le chiffre d'affaires cumulé depuis le début de l'année s'élève à 422,6 M$ (+26 %), le résultat net à 84,7 M$ (+8,8 %). Les flux de trésorerie opérationnels se sont renforcés à 143,9 M$ (+55 %).
La trésorerie, équivalents et placements à court terme ont atteint 659,6 M$ après des rachats d'actions pour 46,1 M$ (1,6 M d'actions) et des dividendes de 17,7 M$ ; il ne restait que 1 M$ sous l'autorisation précédente de 50 M$, mais un nouveau programme de 75 M$ a été approuvé le 31/07/25.
Répartition par segment : CTU 56 % du chiffre d'affaires, AIUS 26 %, USAHS 18 % (perte opérationnelle de 2,0 M$ depuis le début de l'année pendant l'intégration).
Le chiffre d'affaires différé brut est passé à 113,6 M$, reflétant une facturation et des inscriptions accrues ; la provision pour pertes sur créances est stable à 42,3 M$.
Le bilan reste peu endetté ; une cession-bail échouée de 56,8 M$ a généré un passif financier. La trésorerie totale plus les investissements dépassent les passifs de ~675 M$.
Le taux d'imposition effectif a diminué à 27,0 % (bénéfice des compensations en actions et des reprises de provisions).
Réglementaire/juridique : la plainte du DOJ pour violation du False Claims Act et la nouvelle CID restent non résolues ; la provision pour litiges est de 1,5 M$.

Q2 2025 Überblick (Perdoceo Education – PRDO):

Der Umsatz stieg im Jahresvergleich um 25,7 % auf 209,6 Mio. USD, unterstützt durch die Übernahme von USAHS im Dezember 2024 (18 % des Quartalsumsatzes) und anhaltendes Wachstum bei den Bestandsunternehmen.
Das operative Ergebnis kletterte um 11,7 % auf 51,4 Mio. USD; der Nettogewinn stieg um 6,8 % auf 41,0 Mio. USD, was ein verwässertes Ergebnis je Aktie von 0,62 USD gegenüber 0,57 USD bedeutet.
Der Umsatz seit Jahresbeginn beträgt 422,6 Mio. USD (+26 %), der Nettogewinn 84,7 Mio. USD (+8,8 %). Der operative Cashflow verbesserte sich auf 143,9 Mio. USD (+55 %).
Barmittel, Äquivalente und kurzfristige Investitionen erreichten 659,6 Mio. USD nach Aktienrückkäufen im Wert von 46,1 Mio. USD (1,6 Mio. Aktien) und Dividenden von 17,7 Mio. USD; unter der vorherigen Genehmigung von 50 Mio. USD verblieb nur noch 1 Mio., aber ein neues Programm über 75 Mio. USD wurde am 31.07.25 genehmigt.
Segmentmix: CTU 56 % des Umsatzes, AIUS 26 %, USAHS 18 % (operativer Verlust von 2,0 Mio. USD seit Jahresbeginn während der Integration).
Die Brutto-Rückstellungen für Umsatzerlöse stiegen auf 113,6 Mio. USD, was höhere Abrechnungen und Einschreibungen widerspiegelt; die Wertberichtigung für Forderungsausfälle blieb mit 42,3 Mio. USD stabil.
Die Bilanz bleibt schuldenarm; ein gescheiterter Sale-Leaseback in Höhe von 56,8 Mio. USD führte zu einer Finanzverbindlichkeit. Barmittel plus Investitionen übersteigen alle Verbindlichkeiten um ca. 675 Mio. USD.
Der effektive Steuersatz sank auf 27,0 % (Vorteil durch Aktienvergütungen und Rückstellungen).
Regulatorisch/rechtlich: DOJ-Klage nach dem False Claims Act und neue CID sind noch offen; Rückstellung für Rechtsstreitigkeiten beträgt 1,5 Mio. USD.

07/31/2025 - 04:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hollembaek Linda T.

(Last)

(First)

(Middle)

2300 WINDY RIDGE PARKWAY

10TH FLOOR

(Street)

ATLANTA

30339

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
MANHATTAN ASSOCIATES INC [ MANH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/29/2025		S		300	D	$222.1833⁽¹⁾	13,631	D
Common Stock	07/29/2025		S		1,724	D	$221.4181⁽²⁾	11,907	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This is the weighted average sale price for the transactions reported in this line item. These transactions were consummated at prices ranging from $222.1300 to $222.2300. The filing person undertakes to provide full information regarding the number of shares sold at each price upon request by the Securities and Exchange Commission, the Company or a security holder of the Company.

2. This is the weighted average sale price for the transactions reported in this line item. These transactions were consummated at prices ranging from $221.1100 to $222.0300. The filing person undertakes to provide full information regarding the number of shares sold at each price upon request by the Securities and Exchange Commission, the Company or a security holder of the Company.

	/s/ David M. Eaton, Attorney-in-Fact	07/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How did PRDO's revenue perform in Q2 2025?

Revenue rose 25.7 % year-over-year to $209.6 million, aided by the USAHS acquisition.

What was Perdoceo's diluted EPS for the quarter?

Diluted EPS increased to $0.62, up from $0.57 in Q2 2024.

How much cash and short-term investments does PRDO have?

As of June 30 2025 the company held $659.6 million in cash, equivalents and short-term investments.

What is the status of share repurchases?

PRDO bought back 1.6 million shares for $46.1 m YTD; a new $75 m authorization begins 7/31/25.

Are there any significant legal or regulatory issues disclosed?

Yes. A False Claims Act suit and a new DOJ Civil Investigative Demand remain open; no loss estimate has been recorded beyond a $1.5 m legal reserve.

[Form 4] Manhattan Associates Inc Insider Trading Activity

Insights

FAQ

How did PRDO's revenue perform in Q2 2025?

What was Perdoceo's diluted EPS for the quarter?

How much cash and short-term investments does PRDO have?

What is the status of share repurchases?

Are there any significant legal or regulatory issues disclosed?

NASDAQ:MANH

MANH Rankings

MANH Latest News

MANH Latest SEC Filings

MANH Stock Data

Trending News

[Form 4] Manhattan Associates Inc Insider Trading Activity

Insights

Financial Analyst positive

Regulatory & Risk Analyst negative

FAQ

How did PRDO's revenue perform in Q2 2025?

What was Perdoceo's diluted EPS for the quarter?

How much cash and short-term investments does PRDO have?

What is the status of share repurchases?

Are there any significant legal or regulatory issues disclosed?

NASDAQ:MANH

MANH Rankings

MANH Latest News

MANH Latest SEC Filings

MANH Stock Data